Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.47 |
| ▸ | PREP | P48147 | 2/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.32 |
| ▸ | FLT4 | P35916 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | RARB | P10826 | 1/20 | 0.32 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4894756 | 0.80 | DPP4 (0.45) | DPP4DPP9PREPDPP8DPP7 | |
| SCHEMBL4635272 | 0.79 | KDM4E (0.57) | DPP4DPP9PREPDPP8DPP7 | |
| SCHEMBL4635237 | 0.74 | DPP4 (0.47) | DPP4DPP9DPP8KDM4EALDH1A1 | |
| SCHEMBL4635925 | 0.73 | DPP4 (0.47) | DPP4DPP9PREPDPP8DPP7 | |
| SCHEMBL4470692 | 0.72 | EPHA2 (0.47) | DPP4DPP9KDM4EALDH1A1HPGD | |
| SCHEMBL4898070 | 0.71 | DPP4 (0.47) | DPP4DPP9PREPDPP8DPP7 | |
| SCHEMBL185766 | 0.68 | TRPV4 (0.64) | KDM4ETRPV4ALDH1A1 | |
| SCHEMBL4635182 | 0.67 | DPP4 (0.50) | DPP4DPP9PREPDPP8DPP7 | |
| SCHEMBL4635204 | 0.67 | DPP4 (0.47) | DPP4DPP9PREPDPP8DPP7 | |
| SCHEMBL4635979 | 0.66 | GRM1 (0.44) | DPP4DPP9DPP8DPP7KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300251-A1 | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300251-A1 | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors | DPP4, DPP3, DPP8 | DPP4 1/4885DPP9 5/4885PREP 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.